These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

64 related items for PubMed ID: 371974

  • 1. Chelation therapy in beta-thalassemia major: a one-year double blind study of 2,3-dihydroxybenzoic acid.
    Peterson CM, Graziano JH, Grady RW, Jones RL, Markenson A, Lavi U, Canale V, Gray GF, Cerami A, Miller DR.
    Exp Hematol; 1979 Feb; 7(2):74-80. PubMed ID: 371974
    [Abstract] [Full Text] [Related]

  • 2. A randomized double-blind, placebo-controlled study of therapeutic effects of silymarin in β-thalassemia major patients receiving desferrioxamine.
    Moayedi B, Gharagozloo M, Esmaeil N, Maracy MR, Hoorfar H, Jalaeikar M.
    Eur J Haematol; 2013 Mar; 90(3):202-9. PubMed ID: 23278124
    [Abstract] [Full Text] [Related]

  • 3. Combined therapy of silymarin and desferrioxamine in patients with beta-thalassemia major: a randomized double-blind clinical trial.
    Gharagozloo M, Moayedi B, Zakerinia M, Hamidi M, Karimi M, Maracy M, Amirghofran Z.
    Fundam Clin Pharmacol; 2009 Jun; 23(3):359-65. PubMed ID: 19453758
    [Abstract] [Full Text] [Related]

  • 4. [Evaluation of iron overload in thalassemia].
    Piga A, Davico S, Magliano M, Luzzatto L, Sandri A, Gabutti V.
    Pediatr Med Chir; 1986 Jun; 8(1):9-13. PubMed ID: 3725619
    [Abstract] [Full Text] [Related]

  • 5. Iron overload in thalassemia: comparative analysis of magnetic resonance imaging, serum ferritin and iron content of the liver.
    Mazza P, Giua R, De Marco S, Bonetti MG, Amurri B, Masi C, Lazzari G, Rizzo C, Cervellera M, Peluso A.
    Haematologica; 1995 Jun; 80(5):398-404. PubMed ID: 8566878
    [Abstract] [Full Text] [Related]

  • 6. Iron absorption in non-transfused iron loading anaemias: prediction of risk for iron loading, and response to iron chelation treatment, in beta thalassaemia intermedia and congenital sideroblastic anaemias.
    Pippard MJ, Weatherall DJ.
    Haematologia (Budap); 1984 Jun; 17(1):17-24. PubMed ID: 6724353
    [Abstract] [Full Text] [Related]

  • 7. [Chelating therapy in beta-thalassemia].
    Musumeci S, Romeo MA, Di Gregorio F, Schiliró G, Russo G.
    Pediatr Med Chir; 1982 Jun; 4(1-2):55-9. PubMed ID: 7111040
    [Abstract] [Full Text] [Related]

  • 8. Chelation therapy in beta-thalassemia: the benefits and limitations of desferrioxamine.
    Giardina PJ, Grady RW.
    Semin Hematol; 1995 Oct; 32(4):304-12. PubMed ID: 8560288
    [Abstract] [Full Text] [Related]

  • 9. A controlled trial of long-term chelation therapy in homozygous beta-thalassemia.
    Letsky EA.
    Birth Defects Orig Artic Ser; 1976 Oct; 12(8):31-41. PubMed ID: 1009233
    [No Abstract] [Full Text] [Related]

  • 10. Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients.
    Shalitin S, Carmi D, Weintrob N, Phillip M, Miskin H, Kornreich L, Zilber R, Yaniv I, Tamary H.
    Eur J Haematol; 2005 Feb; 74(2):93-100. PubMed ID: 15654898
    [Abstract] [Full Text] [Related]

  • 11. Ascorbic acid status in thalassemia major.
    Tagliabue A, Turconi G, Allegrini M, De Stefano P, Borgna-Pignatti C, Bongo I, Dezza L, Cazzola M.
    Haematologica; 1984 Feb; 69(5):542-8. PubMed ID: 6437931
    [No Abstract] [Full Text] [Related]

  • 12. Study of intermittent intravenous deferrioxamine high-dose therapy in heavily iron-loaded children with beta-thalassemia major poorly compliant to subcutaneous injections.
    Wali YA, Taqi A, Deghaidi A.
    Pediatr Hematol Oncol; 2004 Feb; 21(5):453-60. PubMed ID: 15205089
    [Abstract] [Full Text] [Related]

  • 13. Iron metabolism in thalassemia intermedia.
    Fiorelli G, Fargion S, Piperno A, Battafarano N, Cappellini MD.
    Haematologica; 1990 Feb; 75 Suppl 5():89-95. PubMed ID: 2086386
    [Abstract] [Full Text] [Related]

  • 14. The correlation of transferrin saturation and ferritin in non-splenectomized thalassemic children.
    Wangruangsathit S, Hathirat P, Chuansumrit A, Pakakasama S, Hongeng S.
    J Med Assoc Thai; 1999 Nov; 82 Suppl 1():S74-6. PubMed ID: 10730522
    [Abstract] [Full Text] [Related]

  • 15. [Nuclear magnetic resonance and iron overload in thalassemia].
    Schettini F, De Mattia D, Cavallo L, Sabato V, Santoro N, Del Vecchio GC, Martinelli G, Martinelli A, Di Bartolomeo P, Di Girolamo G.
    Minerva Pediatr; 1991 Dec; 43(12):777-81. PubMed ID: 1798402
    [Abstract] [Full Text] [Related]

  • 16. New treatment for patients with iron overload.
    Griffith P, Burks J.
    J Nurs Care; 1978 Sep; 11(9):12-4. PubMed ID: 308223
    [No Abstract] [Full Text] [Related]

  • 17. The effect of treatment with long-term chelating agents on iron overload in thalassaemia.
    Letsky EA, Flynn DM, Barry M.
    Br J Haematol; 1973 Aug; 25(2):285. PubMed ID: 4726921
    [No Abstract] [Full Text] [Related]

  • 18. Iron chelation in thalassemia: mechanism of desferrioxamine action.
    Hershko C, Rachmilewitz EA.
    Isr J Med Sci; 1978 Nov; 14(11):1111-5. PubMed ID: 750535
    [Abstract] [Full Text] [Related]

  • 19. Decreased natural killer activity in thalassemia major: a possible consequence of iron overload.
    Akbar AN, Fitzgerald-Bocarsly PA, de Sousa M, Giardina PJ, Hilgartner MW, Grady RW.
    J Immunol; 1986 Mar 01; 136(5):1635-40. PubMed ID: 3005397
    [Abstract] [Full Text] [Related]

  • 20. Role of T2* magnetic resonance in monitoring iron chelation therapy.
    Carpenter JP, Pennell DJ.
    Acta Haematol; 2009 Mar 01; 122(2-3):146-54. PubMed ID: 19907152
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 4.